In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cibiem Inc.

Altering the course of heart failure with carotid body modulation

This article was originally published in Start Up

Executive Summary

Cibiem Inc.’s catheter-based CBM system is designed to modulate the carotid body, a tiny group of chemoreceptors located at the fork of the carotid artery that helps regulate respiratory activity. The start-up believes its technology could mean new treatment possibilities for a broad range of diseases including heart failure, where it could address the remodeling that takes place as well as alleviate such symptoms as breathlessness.

You may also be interested in...



Biden Health Plan: Think ‘Health Security,’ Not ‘Medicare For All’

The Democratic Primary focused heavily on the idea of ‘Medicare for All,’ but the emergence of former Vice President Biden as the party standard bearer – and the overwhelming impact of the COVID-19 outbreak – suggests a very different theme for the national campaign.

QUOTED. 3 June 2020. Stephen Hahn.

In a 1 June speech before the Alliance For a Stronger FDA, US FDA commissioner Stephen Hahn stressed the agency’s vigilance in guarding against consumer use of flawed COVID-19 products. He also made comments about the need for doctors to communicate more with patients. See what he said about the use of telehealth here.

House Committees Want BARDA Coronavirus Vaccine, Treatment Contract Info

Request for documents and a briefing is part of efforts to ensure federal programs are ‘protected from price gouging.’

Topics

Related Companies

UsernamePublicRestriction

Register

MT125948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel